A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-27. Anything still debated is marked as such rather than presented as settled.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
=== Treatment === The goals of biomedical waste treatment are to reduce or eliminate the waste's hazards, and usually to make the waste unrecognizable. Treatment should render the waste safe for subsequent handling and disposal. There are several treatment methods that can accomplish these goals. It includes segregating the bio waste. Biomedical waste is often incinerated. An efficient incinerator will destroy pathogens and sharps. Source materials are not recognizable in the resulting ash. Alternative thermal treatment can also include technologies such as gasification and pyrolysis including energy recovery with similar waste volume reductions and pathogen destruction. An autoclave may also be used to treat biomedical waste. An autoclave uses steam and pressure to sterilize the waste or reduce its microbiological load to a level at which it may be safely disposed of. Many healthcare facilities routinely use an autoclave to sterilize medical supplies. If the same autoclave is used to sterilize supplies and treat biomedical waste, administrative controls must be used to prevent the waste operations from contaminating the supplies. Effective administrative controls include operator training, strict procedures, and separate times and space for processing biomedical waste. Microwave disinfection can also be employed for treatment of biomedical wastes. Microwave irradiation is a type of non-contact heating technologies for disinfection. Microwave chemistry is based on efficient heating of materials by microwave dielectric heating effects.
== Self-assembling peptides versus carbon nanotubes == Carbon nanotubes (CNTs) are another type of nanomaterial that have attracted much interest for their potential to serve as building blocks for bottom-up applications. They have excellent mechanical, electrical, and thermal properties and can be fabricated to a wide range of nanoscale diameters, making them attractive and appropriate for the development of electronic and mechanical devices. They demonstrate metal-like properties and can act as remarkable conductors. However, there are several areas where peptides have advantages over CNTs. One advantage is that peptides have almost limitless chemical functionality compared with the very limited chemical interactions that CNTs can perform due to their non-reactiveness. Furthermore, CNTs exhibits strong hydrophobicity which results in a tendency to clump in aqueous solutions and therefore have limited solubility; their electrical properties are also affected by humidity, and the presence of oxygen, N2O, and NH3. It is also difficult to produce CNTs with uniform properties and this poses serious drawbacks as the reproducibility of precise structural properties is a key concern for commercial purposes. Lastly, CNTs are expensive, with prices in the range of hundreds of dollars per gram, rendering most applications commercially unviable.
== Adverse effects == The adverse effects of pethidine administration are primarily those of the opioids as a class: nausea, vomiting, dizziness, diaphoresis, urinary retention, and constipation. Due to moderate stimulant effects mediated by pethidine's dopamine and norepinephrine reuptake inhibition, sedation is less likely compared to other opioids. Unlike other opioids, it does not cause miosis because of its anticholinergic properties. Overdose can cause muscle flaccidity, respiratory depression, obtundation, psychosis, cold and clammy skin, hypotension, and coma. A narcotic antagonist such as naloxone is indicated to reverse respiratory depression and other effects of pethidine. Serotonin syndrome has occurred in patients receiving concurrent antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors, or other medication types (see Interactions below). Convulsive seizures sometimes observed in patients receiving parenteral pethidine on a chronic basis have been attributed to accumulation in plasma of the metabolite norpethidine (normeperidine). Fatalities have occurred following either oral or intravenous pethidine overdose.
== History == Mycophenolic acid was discovered by Italian medical scientist Bartolomeo Gosio. Gosio collected a fungus from spoiled corn and named it Penicillium glaucum. (The species is now called P. brevicompactum.) In 1893 he found that the fungus had antibacterial activity. In 1896 he isolated crystals of the compound, which he successfully demonstrated as the active antibacterial compound against the anthrax bacterium. This was the first antibiotic that was isolated in pure and crystalline form. But the discovery was forgotten. It was rediscovered by two American scientists C.L. Alsberg and O.M. Black in 1912, and given the name mycophenolic acid. The compound was eventually demonstrated to have antiviral, antifungal, antibacterial, anticancer, and antipsoriasis activities. Although it is not commercialised as antibiotic due to its adverse effects, its modified compound (ester derivative) is an approved immunosuppressant drug in kidney, heart, and liver transplantations, and is marketed under the brands Cellcept (mycophenolate mofetil by Roche) and Myfortic (mycophenolate sodium by Novartis). Cellcept was developed by a South African geneticist Anthony Allison and his wife Elsie M. Eugui. In the 1970s while working at the Medical Research Council, Allison investigated the biochemical causes of immune deficiency in children. He discovered the metabolic pathway involving an enzyme, inosine monophosphate dehydrogenase, which is responsible for undesirable immune response in autoimmune diseases, as well as for immune rejection in organ transplantation.
Sources: en.wikipedia.org
== Biomedical Science in the 20th century == At this point in history the field of medicine was the most prevalent sub field of biomedical science, as several breakthroughs on how to treat diseases and help the immune system were made. As well as the birth of body augmentations.
=== Ion mobility spectrometry === Explosive detection using ion mobility spectrometry (IMS) is based on velocities of ions in a uniform electric field. There are some variant to IMS such as Ion trap mobility spectrometry (ITMS) or Non-linear dependence on ion mobility (NLDM) which are based on IMS principle. The sensitivity of devices using this technology is limited to pg levels. The technology also requires the ionization of sample explosives which is accomplished by a radioactive source such as nickel-63 or americium-241. This technology is found in most commercially available explosive detectors such as the GE VaporTracer, Smith Sabre 4000 and Russian built MO-2M and MO-8. The presence of radioactive materials in these equipments cause regulatory hassles and requires special permissions at customs ports. These detectors cannot be field serviced and may pose radiation hazard to the operator if the casing of the detector cracks due to mishandling. Bi-yearly checks are mandatory on such equipment in most countries by regulating agencies to ensure that there are no radiation leaks. Disposal of these equipments is also controlled owing to the high half-life of the radioactive material used. Electrospray ionization, mobility analysis (DMA) and tandem mass spectrometry (MS/MS) is used by SEDET (Sociedad Europea de Detección) for the “Air Cargo Explosive Screener (ACES)”, targeted to aviation cargo containers currently under development in Spain.
== Clinical development == The drug was under development by Roche for treatment of schizophrenia and reached phase 3 clinical trials for this indication by 2019. The phase 2 results of RO5263397 do not appear to have been disclosed as of this date. However, some findings from one clinical study were published in 2015.
== Select publications == Masur, S.K. (1969). "Fine structure of the autotransplanted pituitary of the red eft. Notophthalmus viridescens". Gen. Comp. Endocrin. 12: 12–32. Masur, S.K.; Holtzman, E.; Schwartz, I.L.; Walter, R. (1971). "Correlation between pinocytosis and hydroosmosis induced by neurohypophyseal hormone and mediated by adenosine 3', 5'-cyclic monophosphate". J. Cell Biol. 49: 582–589. Masur, S.K.; Dewal, H.S.; Dinh, T.T.; Erenburg, I.; Petridou, S. (1996). "Myofibroblasts differentiate from fibroblasts plated at low density". Proc. Natl. Acad. Sci. 93: 4219–4223. Maltseva, O; Folger, P; Zekaria, D; Petridou, S; Masur, SK (2001). "Fibroblast growth factor reversal of the corneal myofibroblast phenotype". Invest Ophthalmol Vis Sci. 42: 2490–5. PMID 11581188.. Masur, S.; Kane, C. M. (2001-12-21). "Tapping science's women for the podium". Science. 294 (5551): 2480. doi:10.1126/science.294.5551.2480a. ISSN 0036-8075. PMID 11770518.. Bernstein, AM; Twining, SS; Warejcka, DJ; Tall, E; Masur, SK (2007). "Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation". Mol Biol Cell. 18: 2716–27. doi:10.1091/mbc.e06-10-0912. PMC 1924808. PMID 17507651.. Masur, Sandra Kazahn (January 2013). "Women in cell biology: a seat at the table and a place at the podium". Molecular Biology of the Cell. 24 (2): 57–60. doi:10.1091/mbc.E12-07-0517. ISSN 1939-4586. PMC 3541963. PMID 23307103.. Masur, Sandra K. (2015-08-01). "Invisible woman?". Trends in Cell Biology. 25 (8): 437–439. doi:10.1016/j.tcb.2015.06.001. ISSN 0962-8924.
Whose power is to be balanced? Today, no nation or group challenges American power … In fact, should the balance of power operate in its classical form, it would trigger countermoves by states seeking to pose a counterweight to America's expressed ambitions. According to Leffler's exegesis, Bush has invoked a balance of power vocabulary in purpose to integrate the tradition with the hegemonic dilemma. British Orwell Prize-winning policy analyst, Anatol Lieven, comments: In this conception, however, a phrase "was a form of Orwellian doublespeak. The clear intention actually was to be so strong that other countries had no choice but to rally to the side of the United States, concentrating all real power and freedom of action in the hands of America." The surprising rehabilitation of the balance-of-power term in the 2002 NSS "can be accounted for in terms of mythopoetic function that the terminology serves in the document." It keeps alive the traditional concept in a new unipolar world.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.